Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01018836 · ClinicalTrials.gov registry record · Phase 1
Riluzole and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase 1 study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01018836 is a Phase 1 study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 9 participants.
The verdict
NCT01018836, a Phase 1 study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs, such as riluzole, may make tumor cells more sensitive to radiation therapy. Giving riluzole together with whole-brain radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of riluzole when given together with whole-brain radiation therapy in treating patients with brain metastases.
Interventions
- DRUG riluzole
- RADIATION whole-brain radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2009-11 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01018836
The ClinicalTrials.gov registry entry for NCT01018836 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which riluzole is the first listed.
NCT01018836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01018836 about?
NCT01018836 is a clinical study titled "Riluzole and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases". RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs, such as riluzole, may make tumor cells more sensitive to radiation therapy. Giving riluzole together with whole-brain radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effect...
What is the current status of trial NCT01018836?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2009-11. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01018836?
The interventions under investigation include: riluzole (DRUG), whole-brain radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT01018836?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.